01/29/2024
New publication alert!👩🔬🔬📄
The results highlighted in the Business Wire's publication "Bayer's elinzanetant meets all primary and key secondary endpoints in pivotal OASIS 1 and 2 Phase 3 studies" bring us one step closer to providing effective solutions for folks experiencing menopausal symptoms.
Read more- https://urldefense.com/v3/__https:/www.businesswire.com/news/home/20240108102481/en/Bayer**Bs-elinzanetant-meets-all-primary-and-key-secondary-endpoints-in-pivotal-OASIS-1-and-2-Phase-III-studies__;4oCZ!!Mi0JBg!NNDWH_Yvzf1Z9b9VpUR05dovdZ9qI5x2dJohmdvn-yxi52RfmpTksa1Ql3UD6Y-VVC5Fxrdx9sPvj_6AZ3BkqpaiWw$